|

Liver Cancer Clinical Trials in San Antonio, TX

18 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 1<1 mi
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPhase 3<1 mi
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisPhase 2<1 mi
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsPhase 1<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/2<1 mi
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)Phase 2<1 mi
IDOV-Immune for Advanced Solid TumorsPhase 1<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaPhase 1<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1<1 mi
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPhase 1/2<1 mi
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3<1 mi
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver ImpairmentPhase 1<1 mi
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before SurgeryPhase 2<1 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentPhase 1<1 mi
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment—<1 mi
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma—<1 mi
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentPhase 1<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.